The BCL2 Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from DLD-1 colorectal adenocarcinoma epithelial cells, featuring targeted disruption of the BCL2 gene. This heterogenous knockout pool provides a robust loss-of-function model for investigating apoptosis regulation without the bias associated with single-cell clones. Loss of BCL2 protein function enables dissection of its anti-apoptotic contributions within a native cancer cell signaling environment, facilitating studies that require genetic variability inherent to polyclonal populations.
The parental DLD-1 cell line (ATCC CCL-221) was established from a Dukes?? type C colorectal adenocarcinoma in a male patient. These epithelial cells harbor characteristic oncogenic mutations, including in APC, KRAS, and TP53, and are extensively employed as a model system for colorectal carcinogenesis, metastatic progression, and therapeutic resistance. Their intact apoptotic machinery and colorectal origin make them a physiologically appropriate host for interrogating BCL2-dependent survival pathways in a disease-relevant context.
BCL2 is an anti-apoptotic protein localized to the mitochondrial outer membrane, where it heterodimerizes with BAX and BAK to prevent MOMP, cytochrome c release, and subsequent caspase-9/-3 activation. Expression is driven by transcription factors STAT3, NF-??B, and CREB downstream of cytokine (IL-3, IL-4, GM-CSF) and growth factor (EGF, NGF) signaling via AKT, ERK, and JAK kinases. The p53 pathway induces BH3-only proteins PUMA and NOXA that displace BCL2 from BAX/BAK. BCL2 also interacts with anti-apoptotic (BCL-XL, MCL-1) and pro-apoptotic (BAD, BID, BIM) family members, integrating survival and stress signals.
In colorectal adenocarcinoma, BCL2 overexpression promotes apoptosis evasion and therapy resistance. Disrupting BCL2 in DLD-1 cells permits dissection of its specific contribution to mitochondrial apoptosis regulation. This polyclonal model is valuable for assessing BH3 mimetics like venetoclax and studying adaptive upregulation of MCL-1 or BCL-XL that drives resistance. It also allows exploration of BCL2??s role in autophagy via Beclin-1 interaction.
These cells support diverse apoptosis assays: Western blotting for BCL2, BAX, and cleaved caspases; cytochrome c release quantification; caspase-3/9 activity measurements; cell viability (MTT, CellTiter-Glo) and apoptosis (Annexin V/PI flow cytometry) profiling under drug treatment. Co-immunoprecipitation maps BCL2 interaction networks, and RT-qPCR detects transcriptional changes. Drug sensitivity screens with venetoclax identify resistance mechanisms and synergistic combinations. For further details, contact Ascent Research.
